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ABSTRACT 
CHARACTERIZATION OF T24D1 A(ok809) A PUTATIVE ALPHA-1,2 
GLUCOSYLTRANSFERASE IN C. ELEGANS 
AND 
DETAILED STRUCTURAL ANALYSIS OF THE LIPID LINKED 
OLIGOSACCHARIDE PATHWAY VIA MSN 
by 
William Cobb Wiswall Jr. 
University of New Hampshire, December 2009 
The formation of glycoconjugates, lipids or proteins covalently linked to 
carbohydrate groups in biological systems, is a universal process in every form of 
life studied to date. The carbohydrate moiety of glycoconjugates range in 
complexity from single monomers to intricately branched structures containing 
over a dozen residues. This complexity is further compounded by the 
incorporation of several different monomer types with varying linkage positions 
and branching patterns. The number of possible carbohydrate structures is 
astronomical providing significant challenges to characterize, study, and catalog 
these molecules. Furthermore, assigning biological consequence can be a 
daunting task considering the numerous interactions caused by the infinite 
number of biochemical reactions. Methods often focus on one type of 
glycoconjugate or even a single structure help understand such complexity. The 
projects described here will attempt to examine the role of the lipid-linked 
xi 




A/-glycosylation, a co-translational protein modification process, is 
essential and highly conserved in eukaryotic organisms (Huffaker and Robbins 
1982). In this process, branched chains of oligosaccharides are covalently 
linked to polypeptide chains containing the Asn-X-Ser/Thr consensus sequon 
(Hubbard and Ivatt 1981). A B-A/-glycosidic bond connects the oligosaccharide 
chain to the nitrogen atom of the amide group in an asparagine residue of the 
polypeptide, hence the term /V-glycan. A/-glycosylation occurs in four phases 
beginning on the surface of the endoplasmic reticulum (ER) facing the cytosol; 
synthesis of the glycan precursor on a dolichol anchor molecule forming a lipid-
linked oligosaccharide (LLO); en-bloc transfer of the glycan portion of the LLO to 
the nascent polypeptide; glycan trimming in ER and Gogi, and monosaccharide 
elaboration in the medial and trans Golgi (Burda and Aebi 1999). 
The resulting A/-glycan structures have been shown to substantially 
modulate the intrinsic and extrinsic properties of the glycoprotein potentially 
altering protein folding, half-life, protein-protein binding, and enzymatic activity 
(Varki 1993). Unlike DNA replication, RNA translation or protein synthesis, N-
glycosylation is a non-template driven process constrained by the availability of 
the appropriate enzymes and substrates. The first phase of A/-glycosylation is 
highly conserved in eukaryotes as the mature lipid linked oligosaccharide, 
1 
Glc3Man9GlcNAc2, is the invariable structure transferred to proteins under ideal 
conditions. (Lehle, Strahl et al. 2006) However, Golgi processing enzymes were 
subject to evolution resulting in loose phylogenic associations among higher 
organisms. Golgi processing alters the mature precursor template to produce a 
myriad of glycan structures. Therefore, the repertoire of glycan structures 
produced via the Golgi varies significantly in organisms from different phylogenic 
groups. 
Enbloc transfer 




Figure 1 . Overview of glycoprotein biosynthesis. /V-glycosylation, is a co-translation event since 
the glycan is transferred to the nascent polypeptide as it's threaded through the endoplasmic 
reticulum. Modification of the mature precursor begins in the ER and continues to the Golgi 
apparatus. 
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Resulting /V-glycans are classified into 3 categories; high-mannose, hybrid 
and complex, depending upon the level of Golgi processing and monosaccharide 
elaborations (Komfeld and Komfeld 1985). However, all three types contain the 
conserved trimannosyl core. High mannose glycans are the least modified and 
contain 5 to 9 mannose residues attached to the core GlcNAc and are formed 
from ER/Golgi mannosidase activity. Complex type glycans contain GlcNAc 
residues linked to both branches of the trimannosyl core. These structures can 
be further elaborated with galactose and sialic acid residues. Hybrid /V-glycans 
contain features of both high mannose and complex type as the 1,6 arm consists 
of mannose residues and the 1 -3 is modified with GlcNAc, galactose and sialic 
acid. 
Sialic Acid 
High-Mannose Complex Hybrid 
Figure 2. The three types of A/-glycans 
irt < ) 
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1.1 Biochemistry of the Lipid-Linked Oligosaccharide Pathway 
The lipid-linked oligosaccharide pathway is the initial pathway for 
formation of precursor A/-glycans (Abeijon and Hirschberg 1992). On the surface 
of the endoplasmic reticulum facing the cytosol, the lipid anchor molecule 
dolichol is modified by the addition of specific monosaccharides in a stepwise 
fashion by the appropriate glycosyltranferases (Unligil and Rini 2000). The first 
A/-acetylglucosamine (GlcNAc) residue is added via a pyrophosphate linkage to 
the dolichol backbone from a UDP-GlcNAc donor. The next GlcNAc residue is 
added by a similar glucosyltransferase albeit through a gylcosidic linkage since 
the monosaccharides are linked sequentially. Three mannose (Man) residues 
are then added in a branching pattern by the appropriate mannosyltransferases 
from a UDP-Man donor. Once Man5 GlcNAc2-pp-dolichol is complete the entire 
LLO structure is translocated into the lumen of the ER. This poorly understood 
process is catalyzed by an ATP-dependent, bi-directional flippase (Hirschberg 
and Snider 1987). LLO synthesis is continued with the addition of four additional 
mannose residues. However, the sugar donors in the lumen of the ER are 
composed of dolichol-linked monosaccharides, which are synthesized on the 
exterior surface of the ER and transported independently (Burda and Aebi 1999). 
Finally, glucosyltransferases attach three glucose residues to complete the 
mature precursor structure GIC3Man9GlcNAc2-pp- dolichol. The glycan portion is 
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then transferred en-bloc to the growing poly-peptide chain by a multi-subunit 
enzyme oligosaccharyltransferase (OST) (Knauerand Lehle 1999). 
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D=dolichol F=fructose M=mannose N=/V-acetylglucoamine G=glucose 
Figure 3. The biochemical reactions of the lipid-linked oligosaccharide pathway (LLO). C. 
elegans gene names are labeled for the appropriate homologues. Identified human CDG-1 
genetic mutations are also indicated. 
Loss of function in this pathway inhibits the formation of the final LLO 
precursor which induces hypoglycosylation due to lack of the favored substrate 
for OST. However, kinetic studies revealed that OST can bind and transfer 
incomplete LLO glycans at a lower affinity when the mature precursor is 
structurally deficient (Kelleher and Gilmore 2006). Therefore, truncated LLO 
precursors are transferred to proteins albeit at a lower rate. In the Golgi 
apparatus the protein glycans are trimmed down by enzymes and subsequently 
rebuilt to specificities dictated by local cellular milieu. For this reason, the final 
5 
glycan structure is probably minimally affected by defects in the LLO pathway. 
Instead the major result is the reduction of glycan occupancy (Freeze 2007). 
Upon transfer to the nascent polypeptide, alpha-glucosidase binds to the 
glycoprotein and removes the first glucose residue. Glucosidase II then removes 
the second glucose residue allowing protein folding chaperones calreticulin and 
calnexin to bind to the glycoprotein (Ruddock and Molinari 2006). Following 
protein folding, glucosidase II removes the last glucose residue causing 
calreticulin and calnexin to disassociate from the glycoprotein. This also signals 
UDP-glc: glycoprotein glycosyltransferase (UGGT) to bind to the newly folded 
glycoprotein. This enzyme acts as a sensor and insures proper glycoprotein 
folding. If the glycoprotein is properly folded it is transported to the Golgi for 
processing. If however UGGT detects improper folding (probably by hydrophobic 
interactions) the glycan is reglucosylated allowing the glycoprotein to reenter the 
calnexin calreticulin cycle. (Parodi 2000). This process continues until proper 
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Figure 4. ER and Golgi glycan processing 
In a complex biological system, glycan site occupancy, molecular compositions, 
structural and stereoisomers contribute to a high degree of variability termed 
microheterogeneity. Different glycan compositions at the same site are identified 
as glycomers. Many glycoproteins have a range of glycomer structures, e.g., 
Man5.9 (Rademacher, Parekh et al. 1988). Although, structural variability is a 
result of Golgi glycosyltransferases, site occupancy must result from 




CONGENITAL DISORDERS OF GLYCOSYLATION 
Congenital Disorders of Glycosylation (CDG) are a group of severe multi-
systemic genetically inherited diseases in humans (Jaeken and Matthijs 2001). 
They are categorized into type I or II depending upon the affected pathway and 
subtype denoting the specific gene affected. Type I CDGs are caused by defects 
in the LLO pathway, while types II CDGs are due to glycan processing 
deficiencies. (Freeze 2001). Classical symptoms include cerebellar hypoplasia, 
digestive problems, muscle coordination abnormalities, seizures, and failure to 
thrive. Virtually any system in the body can be affected, which is apparent in the 
variability of symptoms between types, subtypes and even individuals carrying 
the same mutation (Jaeken and Carchon 2001). For this reason, diagnosis is 
only confirmed by isoelectric focusing or genetic analysis. Analysis of LLOs by 
radio labeling and mass spectrometry has been also employed to a lesser extent 
and with limited success (Barone, Sturiale et al. 2009). 
There are approximately 900 CDG patients worldwide, with the majority 
suffering from a mutation in the LLO pathway. CDG la, the most common of all, 
results from a mutation in the phosphomannose mutase gene (PPM) which 
catalyzes mannose-6-phosphate to mannose-1-phosphate (Matthijs, Schollen et 
al. 2000). The carrier allele frequency for CDG-la is as high as 1 in 60 in certain 
8 
populations equating into a possible rate of 1/3600 live births. However, only 
approximately 600 CDG-la patients exist worldwide suggesting this disease is 
misdiagnosed or embryonically lethal in many instances. Indeed, the most 
commonly mutated allele R141H is not observed in the homozygous state and all 
CDG-la patients carry a compound heterozygous gene, or in other words, each 
allele contains a different mutation (Schollen, Kjaergaard et al. 2004). Currently 
only the symptoms of CDG-lb can be ameliorated by the administration of large 
amounts of oral mannose. However, the underlying genetic lesion remains and 



































Developmental delay, hypotonia, 
esotropia, lipodystrophy, cerebellar 
hypoplasia, stroke-like episodes, 
seizures 
Hepatic fibrosis, protein losing 
enteropathy, coagulopathy, 
hypoglycemia 
Moderate developmental delay, 
hypotonia, esotropia, epilepsy 
Profound psychomotor delay, optic 
atrophy, acquired microcephaly, iris 
colobomas; hypsarrhythmia 
Profound psychomotor delay, severe 
developmental delay, optic atrophy, 
acquired microcephaly, epilepsy, 
hypotonia, mild dysmorphism, 
coagulopathy 
Short stature, icthyosis, psychomotor 
retardation, pigmentary retinopathy 
Hypotonia, facial dysmorphism, 
psychomotor retardation, acquired 
































enteropathy, renal failure, 
hypoalbuminemia, edema, ascites 
Normal at birth; developmental delay, 
hypomyelination, intractable seizures, 
iris colobomas, hepatomegaly, 
coagulopathy 
Severe developmental delay, 
hypotonia, seizures, microcephaly, 
exotropia 
Severe psychomotor retardation, 
hypotonia, acquired microcephaly, 
intractable seizures, fever, 
coagulopathy, nephrotic syndrome, 
early death 
Severe microcephaly, hypotonia, 
seizures, hepatomegaly 
Table 1. Congenital Disorders of Glycosylation Type I 
The etiology of CDG types I and II have been apparent since genetic 
studies revealed loss of function mutations in genes associated with 
glycosylation (Marquardt and Freeze 2001). However, understanding the 
pathologies of these diseases has been quite difficult due to the pleiotropic 
nature of these genetic lesions. Most, if not all glycoproteins are defective in 
individuals carrying a homozygous mutation for one of these genes. 
Subsequently the numerous glycoprotein interactions that cause a specific 
pathology are almost impossible to isolate, especially in humans. Therefore, use 
of a genetic model is necessary to circumvent the inherent problems associated 
with A/-glycosylation. 
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2.1 Aberrant AZ-qlycosylation and Disease 
In addition to CDG types I and II, certain glycan structures have been 
associated with other disease states such as cancer. Abnormal A/-glycosylation 
has been associated with tumor proliferation and metastasis. Specifically, an 
increase [3-1,6 branching and over a expression of sialyl lewis X structures have 
been preliminary identified as markers in cancer cell lines (Ogata, Ho et al. 
1995). More recently, novel A/-glycan structural isomers have been identified in 
metastatic brain cells from mouse cancer models (Prien, Huysentruyt et al. 
2008). External environmental agents also have the ability to inhibit proper 
glycan formation. Iso-electric focusing transferrin and a1 -antitrypsin from the 
serum of alcoholics results in a similar pattern to CDG-I patients (Henry, 
Froehlich et al. 1999). These examples reveal the dynamic nature of N-




USE OF C. ELEGANS AS A MODEL ORGANISM 
C. elegans has become a fruitful model system for investigating genetic 
and biochemical aspects of human diseases. Researchers have completely 
mapped the cell lineage, described its anatomy in detail, and sequenced its 
genome (Chalfie, Horvitz et al. 1981) (1998). This present knowledge combined 
with C. elegans' simplistic and short life cycle provides a powerful model system 
to probe biochemical mechanisms. The animal is extremely tractable to genetic 
analysis due to the range and power of the robust methods available. Since 
fundamental processes of development are shared at the molecular level by all 
animals, C. elegans is a suitable analog in which to study profound aspects of 
human development and disease (Brenner 1974). 
Importantly, A/-glycosylation has been a recent target of study in C. 
elegans. The genome contains homologues to mammalian genes involved in 
glycan synthesis, processing and modification (Schachter 2004) C. elegans was 
also identified to contain an active homologue of a glycosyltransferase found in 
humans (Warren, Krizus et al. 2002). Furthermore, RNAi experiments targeting 
oligosaccharyltransferase caused embryonic and larval lethality suggesting N-
glycosylation is essential for development in the worm. Subsequent RNAi 
experiments targeting genes in the A/-glycosylation assembly pathway revealed 
detrimental effects in terms of development. 
12 
Several groups have investigated the A/-glycan structures found on 
glycoproteins in C. elegans by mass spectrometry. Although, C. elegans does 
not produce the same repertoire of mammalian glycans, an abundance of high 
mannose type glycans were identified by al groups. C. elegans does not 
produce sialylated structures found in humans, but instead synthesizes a variety 
of core fucosylated A/-glycans (Hanneman, Rosa et al. 2006 ). Importantly the 
conserved trimannosyl core is found in C. elegans /V-glycans, suggesting a 
conserved LLO pathway. 
C. elegans is also a useful model for analyzing glycan structural 
composition as large amounts are easily produced by large scale growth. 
However, the worm has a thick cuticle that can partially withstand mechanical 
stress. Although LLO glycans can be isolated from C. elegans, mammalian cell 
culture has proven to be more efficient. Therefore, mouse macrophage cells 
were also employed for glycan structural analysis. 
13 
CHAPTER 4 
CHARACTERIZATION OF T24D1 A(OK809) 
The LLO pathway has been well characterized in yeast by knock out 
studies ablating the function of specific glycosytransferases. Although these 
studies provided great detail about the enzymatic pathway, they did not provide 
insight to the role of /V-glycosylation in metazoan or multi-cellular organisms. 
This thesis attempts to expand the experimental line of thought learned in yeast 
to C. elegans. C. elegans provides a simplistic multicellular animal to investigate 
the phenotypic consequences of a defective LLO pathway. 
4.1 Protein Homology of T24D1.4 
Genomic data suggests the existence of C. elegans homologues for all 
LLO glycosyltransferases identified in yeast. Interestingly, none of the C. 
elegans LLO genes have been cloned or characterized. T24D1.4 is a C. elegans 
homologue to the characterized yeast ALG10/DIE2 gene, the last 
glycosyltransferase in the LLO pathway that catalyzes the formation of the 
mature precursor Glc3Man9GlcNAc2-pp-dolichol (Burda and Aebi 1998). 
T24D1.4 is also homologous to the human ALG10/DIE2 gene. 
14 




















C e/egans TAG-179 protein contains 
similarity to Pfam domain PF04922 
DIE2/ALG10 family contains similarity to 
Interpro domains IPR016900 (Alpha-1. 2 






1 2 glucosyltransferase of the ER, functionb 
in the pathway that synthesizes the dohchol-
linked oligosacchande precursor for N-linked 
protein glycosylation. 
SubName: Full=Putative uncharacterized 
protein T1E22_170 
Table 2: Wormbase gene homology report. T24D1.4 contain homologous protein sequences to 
homo sapiens alpha 1,2-glucosyltransferase and yeast ALG10. Reproduced from wormbase.org. 
Yeast, 125 VPYEFIDEKFHVGGTLTYLKGKWTQWDPKITTPPGIYILGLI SYYCIKPI 
C. elegans, 43 VPEPYMDUFHITQTRSYCSGNYS-WNELITTPPALYVISMPLCGGNERYANSI 
Yeast, 240 ILQSLSCVLTLPFGPVKSIWLSAPFAGVSCLFROTNIIWTGFIMILAVERPAIL 
C. elegans, 162 VIWGFS IGNPIASAFLFLISILTRQTHIIWAAIYAF SVIA 
Yeast, 295 LKLFlHAIDDFSNLVLPYMKNFVLFFIYLIWHR-SITliGDKSSHSAGLHIVQlF 
C. elegans, 203 IiKIIISTA--FS--LWPFITLAIGPAMFIYFNDFQlVLGDAKAHQPKFHVAQFF 
Yeast, 354 TVFSLPIWISRNFMKLYRLRIKRKPVQTFFEFIGIMLIIRYFTKVHPFLLAPNR 
C. elegans, 259 AAHTWTQIIPNLLSHLRHLTDMKSLVLQAV VAVLVYYYSYDHPYLLABNR 
Yeast, 419 HYTFYLFRRLIGN 
C. elegans, 320 HFTFYIWRRFLAN 
Figure 5. Amino acid sequence comparison of the predicted C. elegans T24D1.4 protein to the 
characterized yeast ALG10 protein. This figure includes regions containing the highest amino 
acid similarities. 
T24D1.4 and ALG10 are orthologs based upon a reciprocal blast test. 
The protein sequence of T24D1.4 was blasted to the yeast protein database and 
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the top match returned was ALG10. The yeast ALG10 protein sequence 
identified was then blasted against the C. elegans protein database which 
returned only T24D1.4 as the only possible match. 
Sequences producing significant alignments Score E-Value 
YGR227WALG10/DIE2 183 1.2e-17 
YAL037C-B 75 .27 
YGL194C-A 54 .84 
YGR036C 64 .96 
YMP.3Q6W 68
 197 
Table 3. Blast results from submitting the T24D1.4 protein sequence against the yeast protein 
database. 
Sequences producing significant alignments Score E-Value 
^m^:'r\^:c:<:'^\^'^''?- .-,,%.' 101 s.oe-22 
Table 4. Blast results from submitting the yeast ALG10 protein sequence against the C. elegans 
protein database 
The Oklahoma Knock-Out Consortium had created a knock out strain 
deleting the T24D1.4 gene. This strain, (ok809), was acquired by the Warren lab 
since it was the only knock-out of known LLO glycosyltransferases in C. elegans. 
Theoretically, a mutation or knock out in this gene should be the least deleterious 
since Glc2MangGlcNAc2-pp-dolichol is formed, a lower affinity substrate for OST. 
Therefore, this strain would be easier to work with than a mutation that produces 
severely truncated LLOs that would not be transferred efficiently by OST. 
16 
4.2 Specific Aims 
The overall goal of this project was to characterize T24D1 A(ok809) in a 
similar manner to the ALG yeast genes. This would provide a genetic model of 
CDG-I and a non-chemical inhibitor method to study the effects of 
hypoglycosylation. 
In addition to the gene homology, several criteria needed to be addressed 
to establish T24D1 A(ok809) as a model for CDG-I. 
I) A/-glycosylation should defective although not absent in the mutant 
background. 
II) The mature precursor Glc3Man9GlcNAc2 should be absent if alpha-1,2 
glucosyltransferase activity was null. 
III) The strain should display several phenotypes as hypoglycosylation 
would affect numerous pathways. 
4.3 Materials and Methods 
T24D1 A(ok809) animals were obtained from the Oklahoma Knock out 
consortium. Upon arrival they were plated to several large Nematode Growth 
Media (NGM) plates for cultivation. The strains contained a balancer 
chromosome because the strain was believed to contain a lethal allele. Once 
the strain was out crossed 4 times with wild type C. elegans, the balancer was 
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removed and the strain was able to propagate. The knockout was confirmed to 
be present by PCR. This was accomplished by creating primer sets that could 
distinguish the difference between the wild type and deletion alleles of ok809. 
Complementation tests were conducted with egl-33, to ensure this was not 
a previously identified gene. Egl-33 and T24D1 A(ok809) share similar 
phenotypes, and egl-33, although never cloned, was mapped to a position near 
T24D1 A(ok809) (Trent, Tsuing et al. 1983). Complementation analysis revealed 
that T24D1 A(ok809) was not the same gene as egl-33. 
To address the hypoglycosylation question, we adapted a protein 
glycoform western blot assay (Cipollo and Trimble 2002). In our experiment, we 
chose calsequestrin (CSQ-1), an ER localized protein that has been well 
characterized in C. elegans. It is known to have two A/-glycosylation sites that 
are occupied 100% of the time (Cho, Oh et al. 2000) (Cho, Ko et al. 2007). By 
running this protein on a 12% SDS page gel and visualizing the protein on a 
western blot, different glycoforms can be detected as band shifts, doublets or 
triplets. 
SDS- PAGE gels were made from scratch. The separating gel was made 
with 6 ml of 30% acrylamide, 3.75 ml of Tris HCL (pH 8.8), 0.15 ml of 10% SDS, 
5.1 ml of ddH20, 50ul of 10% Ammonium persulfate (APS) and 10 ul of temed. 
The stacking gel was composed of 1.25ml_ of 0.5 M Tris HCL (pH 6.7), 0.65 ml_ 
of 30 % acrylamide, 3.0 ml_ of ddH20 50 \i\ of 10% SDS, 22 ul of 10% APS, and 
15 (al of temed. The amount of protein loaded from each sample was calculated 
by a Bradford Assay each time. Sample protein from T24D1 A(ok809) and wild 
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type C. elegans was boiled for 4 min with 10j.il of loading buffer and 4ul of (3-2 
mercaptoethanol. Gels were run at 200V for 90 min. Blot membranes were 
briefly immersed in MeOH followed by a solution of Tris buffer containing 20% 
MeOH and 1 % SDS. Electro-transfer was completed overnight at 30V in a cold 
room. The following day, the membrane was washed 3 times with 100% MeOH 
and left to dry between filter paper. The primary antibody was rabbit anti-CSQ-1, 
and the working concentration was diluted to 1:5000. The secondary antibody, 
conjugated horse radish peroxidase, was acquired from sigma and diluted 
1:50000. 
Next the LLO precursors were analyzed via MALDI-TOF CFR. Batches 
of wild type and T24D1 A(ok809) C. elegans were grown on large trays 
containing NGM seeded with RR1 E. coli bacteria. Synchronized L1 were 
allowed to propagate for approximately 6 days. Upon clearing of the bacteria, 
the C. elegans were washed off the plates and cleaned by sucrose flotation. 
Harvested animals were placed into a 30% sucrose solution and centrifuged at 
160g. In this method, only live animals float to the surface while dead animals 
and debris collect on the bottom. Live worms are pipetted off to a fresh tube 
containing 100% dHaO. Following three dHaO washes to remove any excess 
sucrose, the animals were flash frozen and stored at -80°C. 
The LLO extraction protocol was adapted from experiments involving 
HPLC for analysis (Grubenmann, Frank et al. 2004). Worm pellets were 
subjected to disruption with a polytron or Barocyler (Pressure Biosystems, South 
Easton, MA). C. elegans pellets of approximately 1.5g were dried down to 
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remove excess water prior to LLO extraction. The pellets were then extracted 
twice with 2:1 chloroform:methanol and the aqueous layer was discarded. The 
remaining pellets were next extracted twice with 10:10:3 chloroform: methanol: 
water. The aqueous layer was removed and dried under nitrogen gas flow. The 
dried extract was then incubated in 0.2 M HCL in 50% isopropanol for 1 hr. This 
hydrolyzes the pyrophosphate bond freeing the glycan from the dolichol 
backbone. The sample was dried again under nitrogen gas flow to remove the 
solvent and acid. The dried extract was then dissolved in 2% acetonitrile 
(AcCN) and checked for acidity with pH strips. Two reverse-phase columns 
were prepared. First a C18 which was washed with 5ml of MeOH, 5ml of AcCN, 
5ml of 3:1 AcCN, and 6ml of 2% AcCN. The sample was then applied to the 
column and allowed to flow through by gravity. The flow through was collected 
and the column was washed with 3ml of 2% AcCN. The second was a porous 
graphitized carbon (PGC) which was prepared for the next column. The sample 
was then applied to the PGC column and washed with 6ml of 2% AcCN. The 
glycans were eluted with 5 ml of 3:1 AcCN: H2O. Finally the sample was dried in 
a SpeedVac (Savant, Holbrook, NY). The samples were then spotted onto a 
MALDI-TOF target plate with 10mg/ml of DHB in 50% AcCN. Spectra were 




4.4.1 Calsequestrin Hvpoqlycosylation Blot 
CSQ-1 in a wild type background has been shown to be synthesized with 
two /V-linked glycan chains. This was confirmed and visualized in this study as 
one band at the expected molecular weight of 64kD. Treatment with endo-H 
caused the wild type band to migrate further, suggesting the removal of two 
glycan chains. In the T24D1 A(ok809) background, CSQ-1 was visualized as 
two distinct bands, possibly indicating the presence of two glycoforms. 
Treatment with endo H collapsed the two bands into one, supporting the idea of 











Figure 6. Calsequestrin western blot from wild type and T24D1 A(ok809) protein preparation. 
This blot was completed as a test run for the CSQ antibody. The T24D1 A{ok809) band appeared 












Figure 7. Calsequestrin western blot with and without endo-H treatment. Although the 
background noise is significant, the T24D1 A(ok809) CSQ-1 migrated as two distinct bands. 
Endo-H treatment of the T24D1 A(ok809) protein caused CSQ-1 to migrate as one band. 
4.4.2 MALDI -TOF CFR of LLP Precursor Glvcans 
Spectra acquired from the wild type C. elegans sample on the MALDI-TOF 
CFR revealed peaks consistent with molecular weights of LLO precursors. 
Peaks representing Man5GlcNAc2 through Glc3Man9GlcNAc2were observable. 
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Figure 8. MALDI-TOF Profile of Wild Type C. elegans LLOs 
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Figure 9. MALDI-TOF Profile of T24D1 A(ok809) C. elegans LLO 
Results for T24D1 A(ok809) were similar in that Man5GlcNAc2 through 
Glc2Man5GlcNAc2 could be identified. However, the mature precursor GIC3 
Man5GlcNAc2 was not detectable. This was consistent with the 
hypoglycosylation blot and expected results inferred from gene homology with 
ALG10. 
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4.4.3 Phenotypic Analysis 
Although C. elegans hermaphrodites contain only 959 cells, a trained 
person can easily recognize many different phenotypes. They are easily 
employed as markers for genetic crosses and distinct phenotypes can also 
provide insight into the biology behind the genetic mutation. Since 
T24D1 A(ok809) had several conspicuous phenotypes, the appropriate assays 
were performed to quantitatively analyze them for comparison. 
The first phenotypic analysis quantitatively confirmed a brood size 
deficiency for the T24D1 A(ok809) strain. The data indicates that the mutant 
knockout strain produces a lower amount of viable progeny compared to the wild 
type counterpart at optimal growing conditions of 20°C. Wild type C. elegans 
typically lays approximately 280 eggs per brood, while the T24D1 A(ok809) strain 
lays 90 eggs per brood on average. 
In addition, T24D1 A(ok809) appears to be a temperature sensitive mutant 
as the number of viable progeny decreases at 25°C. It was noted that a large 
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Figure 10. C. elegans brood sizes at 15°C, 20°C and 25°C, wild type (N2) compared to 
T24D-\ A(ok809) 
The obvious brood size insufficiency suggested an embryonically lethal 
phenotype combined with an egg laying defect. To investigate this phenotype, 
T24D1 A(ok809) was assayed for sensitivity to serotonin and imipramine which 
normally induces egg laying in wild type C. elegans. This assay indicated that 
T24D1 A(ok809) share a phenotype close to the egl-A class of animals 
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categorized by Trent and Horvitz. Serotonin and Impramine did not induce egg 
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Table 5. Egg laying deficiency assay. 
In addition to the obvious brood size deficiency, T24D1 A(ok809) animals 
grew extremely slowly. Furthermore, generation time was significantly 
desynchronized compared to wild type animals that generally reach the 
reproductive stage at approximately 70 hours. 
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Figure 11. Generation time of T24D1 A(ok809) compared to wild type(N2) C. elegans. 
T24D1 A(ok809) animals were tested for sensitivity to tunicamycin, a 
potent inhibitor of A/-glycosylation. Tunicamycin prevents the transfer of the first 
GlcNAc to the lipid carrier dolichol phosphate, essentially inhibiting the first step 
of the LLO pathway. (Tkacz and Lampen 1975). At 3u.g/ml of tunicamycin wild 
type C. elegans displays multiple phenotypes expected from defective 
glycosylation. Doses above 3u.g/ml cause a high percent of larval lethality in wild 
type animals. 100% lethality is observed at between 5ug/ml and 10ug/ml. 
T24D1 A(ok809) animals display a high sensitivity to low doses of tunicamycin. 
Effects are observed at only 0.02u.g/ml of tunicamycin. Doses at or above 
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Figure 12. Tunicamycin sensitivity assay. Wild type (N2) C. elegans compared to T24D1.4 
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4.5 Conclusions 
Experiments completed in this project support the hypothesis that 
T24D1.4 is the C. elegans homologue of the yeast ALG10 gene. The hypo-
glycosylation blot clearly showed that the CSQ-1 protein migrates as two distinct 
bands in the T24D1 A(ok809) strain. This was even more evident when 
examining the blot photo on a light box. When treated with endo-H the 
T24D1 A(ok809) band migrates as one band at a lower molecular weight. In 
addition, the endo-H treated T24D.1 (ok809) band migrates at a similar molecular 
weight as the wild type control treated with endo-H. This change in migration 
when treated with endo-H can be attributed to a loss of A/-glycan chains. 
Therefore, the CSQ-1 doublet observed from T24D1.4(o/c809) is most likely 
produced from different amounts of glycan chains. This suggested that 
T24D1 A(ok809) produces CSQ-1 as different two different glycoforms. This 
result is comparable to the ALG experiments examining protein 
hypogylcosylation. 
The MALDI-TOF analysis revealed the expected LLO compositions in the 
wild type control. The T24D1 A(ok809) profile contained many of the expected 
LLO compositions with the important exception of the mature precursor. This 
peak should appear at a m/z of 2392. Man5GlcNAc2 through GIC2Man9GlcNAc2 
were clearly identifiable in this sample. The lack of the GIC3Man9GlcNAc2 is a 
negative result which can be problematic for providing a definitive answer. 
However, this result is in agreement with the hypoglycosylation blot and genomic 
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data. It is likely that T24D1 A(ok809) does not produce the mature LLO 
precursor. 
Phenotypic analysis revealed multiple defects in terms of development 
indicating a pleiotropic effect as expected. From simple observation using a 
light microscope T24D1 A(ok809) animals carries the following phenotypes; 
dumpy (short, or football shaped), uncoordinated (does not travel in a normal 
sinusoidal movement), growth impaired, (generation time is longer the 3 days), 
and embryonic lethal (noticeable amount of eggs do not hatch to the first larval 
stage). T24D1 A(ok809) animals were hypersensitive to low doses of 
tunicamycin, displaying effects at 0.02u.g/ml. 
The brood size assay indicated that T24D1 A(ok809) animals laid 
approximately 80-90 eggs per brood, which is well under the expect wild type 
size of 280. This phenotype was exacerbated when the animals were grown at 
25°C, resulting in only approximately 15-20 viable animals per brood. 
T24D1 A(ok809) animals were not sensitive to imipramine or serotonin. 
These neural transmitters induce egg laying in wild type animals. 
T24D1 A(ok809) was similar to egl-A class of egg laying defective mutants 
classified by the Horvitz lab which are associated with improper vulva function or 
the vulval and uterine muscles (Trent, Tsuing et al. 1983). The etiology of the 
egg laying defect in T24D1 A(ok809) could also be caused by neuronal defects, 
however, this would require further investigation. 
Hypersensitivity to tunicamycin could also indicate a deficient 
glycosylation pathway in T24D1 A(ok809) animals. This could be inferred as an 
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additional perturbation to the LLO pathway resulting in severe (larval lethality) 
phenotypic effects. 
4.6 Future Work 
Overall, T24D1 A(ok809) meets all of the previously determined criteria to 
classify this mutant as a alpha 1,2 glycosyltranferase. This strain may be used in 
place of glycosylation chemical inhibitors to study the physiologic effects of 
hypoglycosylation. Future work could include genome wide screen for 
suppressor genes or synthetic lethal genes. The easiest method to screen for 
these genes would involve a RNAi screen. The T24D1 A(ok809) strain would be 
crossed with the rrf-3 strain to create a double mutant sensitive to RNAi. 
Individual RNAi constructs could be fed to the strain via bacterial lines. 
Originally, candidate genes identified from the RNAi screen performed in the 
Warren Lab were to be further investigative by this method. 
Phenotypic assays provide a method to identify specific pathologies 
caused by hypoglycosylation and targets for future investigation. Several 
assays indicate a severe egg laying defect, a potential target for investigate the 
role of A/-glycosylation in development. For example, neuronal migration could 
be studied in correlation with GFP studies of T24D1.4. In general, it would be 
interesting to examine the temporal and cellular location of the gene expression 




COMPARATIVE STRUCTURAL ANALYSIS OF LIPID LINKLED 
OLIGOSACCHARIDES IN C. ELEGANS AND MOUSE MACROPHAGE CELLS 
The advent of sequential mass spectrometry (MSn) with ion trap analyzers 
has identified numerous glycan structural isomers on a small subset of 
glycoproteins. Biological significance has also been implied by the 
characterization of unique glycan isomers associated with metastatic brain 
tumors in mouse models. (Prien, Huysentruyt et al. 2008). Msn provides 
paramount sensitivity and comprehensive glycan structural information while 
utilizing small sample amounts. These characteristics provide an inclusive 
platform to study the transient molecules of the LLO pathway. 
The objective of this project was to perform a comparative analysis of 
LLO structural isomers found in C. elegans and mammalian cells. The discovery 
of unique glycan isomers on proteins questions the specificity of entire 
glycosylation pathway and presents the challenge to identify the source of these 
isomers (Prien, Ashline et al. 2009). However, the presence of LLO structural 
isomers does not infer a direct link to ones found on proteins. Multiple 
exogylcosidases in the ER and Golgi are able to trim down the Glc3Man9GlcNAc2 
structure. Since glycans are extensively modified in the Golgi, the 
Glc3Man9GlcNAc2 structure is only transiently present on the glycoprotein. 
Therefore, A/-glycan isomers found on proteins are most likely a result of Golgi 
processing. Furthermore, some studies suggest that LLO intermediates 
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extracted and isolated from cells may be an artifact of the process itself. This 
theory explains that upon cell lysis LLOs normally contained to the ER in vivo are 
exposed to degradation enzymes. However, our study shown here and 
experiments performed by the Lehrman group suggest this process only 
minimally effects the glycan structure of the LLOs (Gao and Lehrman 2002). 
The Golgi glycan processing pathway suggests that there would be no 
reason to catalogue specific isomers in the LLO pathway since these structures 
would be invariably discarded. However, identifying the 
exact glycan isomers created in this pathway could 
potentially be useful for disease markers. In addition, 
current literature presents definitive detailed structures 
based upon methods incapable of distinguishing 
structural isomers (Kelleher, Karaoglu et al. 2001). 
Therefore, this method at the very least will provide 
additional insight to the nature of this pathway. 
Furthermore, this method could be easily employed to 
provide an addition method for CDG diagnosis without 












Figure 13. The expected structure for the 
mature LLO. Current theory definitively uses 
this linkage and construction order. 
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5.1 Sequential Mass Spectrometry 
As an analytical tool, mass spectrometry has been a powerful technique 
employed for the detection and characterization of biopolymers. The diverse 
applications offered by mass spectrometry combined with its inimitable sensitivity 
provide a reliable method to uncover structural details of complex carbohydrates. 
Specifically, sequential mass spectrometry (MSn) with ion-trap analyzers has 
allowed for unprecedented detection and analysis of carbohydrates. (Ashline, 
Singh et al. 2005). 
By preparing glycan samples as methyl derivatives, ion-trap mass 
spectrometery (ITMS) provides an effective method for uncovering carbohydrate 
structural detail and isomers in biological samples. This is based upon the ability 
to disassemble parent ions and separate the resulting fragment ions in the gas-
phase for subsequent fragmentation. Furthermore, the fragmentation pathways 
are reproducible so that spectra data represents the structure of the parent ion 
(Ashline, Lapadula et al. 2007). Although glycan structural isomers have the 
same molecular composition, they fragment through different pathways in the 
gas-phase. Therefore, this method allows for structural elucidation without 
additional separation techniques. 
Permethylation of the carbohydrate analyte is an essential perquisite for 
purification and subsequent MSn analysis. Permethylation transforms hydroxyls 
to methyl ethers (Ciucanu and Kerek 1984). This changes the normally 
hydrophobic carbohydrate to a lipophilic derivative and allows for extractions in 
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non-polar solvents. Even more important, blocking hydroxyls with methyl 
groups allows for the identification of carbohydrate topology since CID 
fragmentation results in hydroxyl scars. These scars are identifiably through 
mass spectrometry since the loss of a methyl group is reflected by a loss in 
mass. 
ITMS combined with permethylation can also provide in depth structural 
information through fragmentation of smaller oligosaccharides. Fragmentation of 
disaccharides and trisaccharides produces cross ring cleavages through a retro 
Diels- Alder reaction. The resulting spectra provides diagnostic ions that reflect 
linkage, branching detail and even anomerocity configurations. 
Previously, investigations in the LLO pathway employed enzymology, 
HPLC coupled with radiolabeling , or fluorophore-assisted carbohydrate 
electrophoresis (Lehrman and Gao 2003) (Frank and Aebi 2005). Although 
these techniques are valuable in identifying the components of the LLO pathway 
in comparison between molecular compositions, they fail to discern structural 
isomers. This project extends ion-trap applications to the lipid linked 
oligosaccharide pathway. 
5.2 Materials and Methods 
Several grams of C. elegans were harvested by large scale growth for 
LLO glycan structural analysis. The protocol was followed as described 
previously in chapter 4 with alterations stated here. Dialysis of sample 
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preparations was completed after cell lysis or C. elegans cuticle disruptions. This 
was incorporated into the procedure to move any free glycans. Dialysis 
cassettes with a molecular weight cutoff of 2KDa were used. Dialysis was 
performed for 3 hours in 20mM ammonium bicarbonate (NH4C03). 0.05% and 
sodium dodecyl sulfate (SDS) at 4°C. This was followed by an overnight dialysis 
in 10mM NH4CO3 and 0.02% SDS. Extractions and column purification were 
performed as described in chapter 4. Following PCG cleanup, the samples were 
dried down in a SpeedVac (Holbrook, NY) and reduced by the addition of 200u.l 
of 10mg/ml NaBH4 in 0.1 M NaOH. After an overnight incubation at room temp 
the reaction was stopped by the addition of three drops of glacial acetic acid and 
dried down again in a SpeedVac (Holbrook, NY). The following additions were 
then added and evaporated consecutively under nitrogen to remove borate 
esters; 3mls of methanol, 3 ml of 1% actetic acid in methanol, followed by 3 ml of 
toluene repeated twice. To remove the salts, the reduced LLO samples were 
run on DOWEX AG50 W X8-400 cation-exchange resin (Sigma-Aldrich, St. 
Louis, MO). The column was washed with 2 ml of HPLC H2O. The flow-
through was collected and dried in the SpeedVac (Holbrook, NY). Samples were 
then permethylated by the following procedure. 1ml of DMSO and 100u.l of 
iodomethane were added to both samples with crushed sodium hydroxide. 
Samples were vortexed at room temp for 1 hr. The reaction was stopped by the 
addition of 1ml_ of HPLC H2O while the samples were on ice. This was followed 
by the addition of 1 mL of dichloromethane. The samples were vortexed and the 
bottom organic layer was removed and saved in a new tube. This processed 
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was repeated three times. The removed organic layer was then washed with 1 
ml of HPLC H2O. This was repeated six times, saving the top organic layer each 
time. The sample was then dried down under nitrogen and lyophilized overnight. 
Samples were analyzed on a LTQ mass spectrometer (ThermoFinnigan, 
San Jose, CA) equipped with a TriVersa Nanomate (Advion, Ithaca, NY) for 
sample infusions. Collision energy was set to 35%. Activation Q was set to 0.25. 
Scans were acquired in the positive mode. 
Testing for in vivo glycan degradation was accomplished by incubating 
standard GIC3Man3 with mouse macrophage cell lysates for 6 hours at room 
temp. Following incubation the LLOs were isolated as previously described. 
5.3 Results 
5.3.1 LLOs are not substantially Degraded Upon Cell Lysis 
Personal communication with the Gilmore lab suggested that LLO isomers 
identified by MSn could be an artifact of cell lysis. In order to test this hypothesis 
Glc3Man9 standard were incubated with cell lysates from mouse macrophage 
cells. The LLOs were subsequently re-purified and analyzed by MALDI-TOF-
CFR. The results indicated that the GIC3Man9 standard was not degraded as the 
major peak of m/z 1907.9 was still present. Compared to the pure standard, the 
spectra from the incubated LLOs contained higher background noise and peaks 
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Figure 15. MALDI-TOF-CFR profile of Glc3Man9 standard re-purified after an 8 hr incubation in 
fresh mouse macrophage cell lysate. Other peaks present did not correspond to any possible 
glycan degradation products from Glc3Man9. Profiles 1-1000 
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5.3.2 Comparative Structural Analysis MangGlcNAc? LLP 
Analysis of the conserved tri-mannosyl core revealed an isomeric mixture 
of two structures in C. elegans. The expected structure containing a1,6 and a1,3 
linkages at the first mannose residue was determined by the following pathway: 
m/z 1187.6 -»• m/z894.3 -> m/z 737.3 -»• m/z 519.2. The MS5 spectra revealed 
the diagnostic m/z431 (35 A-ion) suggesting the presence of an a1,3 linkage. 
The m/z 401 (2'4 A-ion) suggests an crt ,6 linkage. 
Alternatively, a linear core structure is observed in the following 
fragmentation pathway: m/z 1187 —* m/z 894 —»• m/z 667. MS4 spectra of this C-
ion produced an m/z 472 fragment only consistent with an internal mannose with 
only one open hydroxyl group. Normally, the branching mannose contains two 
open hydroxyl groups corresponding to a peak of m/z 458. This peak was also 
observed indicating a mixture of a branching and linear structure. 
Analysis of Man3GlcNAc2 in mouse macrophage cells also revealed the 
expected core branching structure containing a1,6 and a1,3 linkages. Again, 
MS4 of the m/z 667(C-ion) produced an m/z 472 peak indicating a linear core 
structure. 
The mouse macrophage contained an unusual terminal HexNAc structure. 
This was apparent from the m/z 928(Y-ion) observed from MS2 fragmentation of 
the m/z 1187.6. This can only be explained by the loss of a terminal HexNAc. In 
addition, this would indicate the presence of only 1 HexNAc at the core. 
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Figure 16. MS4 pathway of the m/z 1187.6, Man3GlcNAc2 LLO from C. elegans. 
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Figure 17. MS5 spectra of 1187.6 m/z, Man3GlcNAc2 LLO from C. elegansand fragmentation 
assignment for the m/z 519 ion The cross ring cleavages produce diagnostic ions of m/z 329, m/z 
375, and m/z 401, m/z 431 indicating a mixture of a1,6 and a1,3 linkages at the core. This 
structure is the expected glycan precursor Man3GlcNAc2. 
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Figure 18. MS4 spectra of m/z 1187.6, Man3GlcNAc2 LLO from C. elegans and ion fragmentation 
assignment of the m/z 667 C-type ion. 
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Figure 19. MS4 spectra of m/z 1187.6, Man3GlcNAc2 LLO from C. elegans and ion fragmentation 
assignment of the m/z 676 Y-type ion. The m/z458 and m/z 472 indicate a mixture of linear and 
branching core structures. 
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Figure 20. MS4 spectra of m/z 1187.6, Man3GlcNAc2 LLO from mouse macrophage cells and ion 
fragmentation assignments of the m/z 676 Y-type ion. 
44 





6 6 7 . 3 \ 
894.3 (BY°°i MS
2






400 600 800 m/z 1000 1200 1400 
m/z 1187.6 
400 ' ' 
737.3 




800 nvi 1000 1200 
m/z 1187.6 
M e 0 > 0 M 8 
' — < / - O M G 
Figure 21 . Comparison of the MS2 spectra of the m/z 1187.6. In the C. elegans sample (panel 
A) m/z 894.3 is an expected peak representing the loss of a reducing end HexNAc. In the mouse 
macrophage sample (panel B), the major peak is m/z 928.4, only explainable by the loss of a 
terminal HexNAc. 
Further investigation of the terminal HexNAc found in mouse macrophage 
suggests a core branching structure with the terminal HexNAc on the a1,6 arm. 
This was identified by the MSn pathway m/z 1187.6 -»• m/z 928.4 -»• m/z 724.5. 
At the MS4 level, the m/z325 and m/z 375 suggest the a1,6 linkage. The m/z 
520 found in the MS3 spectra also reveals a linear structure. However, this was 
not confirmed at the MS level as the m/z520 was not present. 
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Figure 22. MS4 pathway of the m/z 1187 isolating the terminal HexNAc structure from mouse 
macrophage cells. 
In summation, Man3GlcNac2 LLO in the C. elegans and mouse 
macrophage is composed of 3 glycan structural isomers; the expected core 
branching structure, a linear core structure, and an unexpected terminal HexNAc 
structure. 
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MS" Pathways- Man3GlcNAc2 LLO Consistent 
Topologies 
1 
1187.6 -» 969.5 (loss of O ) -> 676.3 (loss of - • ) -> 458.1 
1187.6 
of P ) 
894.4 (loss of • • ) -»• 676.3 (loss of O ) - • 458.1 (loss 
1187.6 -» 894.4 (loss of - • ) -> 737.3 -» 519.2 ( loss of O ) 
1187.6 -> 894.4 (loss of - • ) -> 667.2 -> 563.2 
1187.6 -> 894.4 (loss of - • ) -» 667.2 -> 472.2 
1187.6-+928.4 (loss of 1 
Table 6. Table of the MSn pathways analyzed and the corresponding topologies for m/z 1187.6, 
Man3GlcNAc2. 
5.3.3 Comparative Structural Analysis MaruGlcNAc? LLO 
MSn disassembly of the m/z 1391.6 ion in C. elegans revealed an 
unexpected tri-branching core isomer which was not seen in mouse macrophage 
cells. Both samples contained the typical core branching structure and the linear 
core structure uncovered in the Man3GlcNAc2 composition. The tri-branching 
structure was ascertained by the following MSn pathway: m/z 1391.5—* m/z 
1098.4^m/z 880.3 - * m/z 662.2. 
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Figure 23. MS4 spectra of m/z 1391.5 Man4GlcNAc2 LLO from C. elegans and ion fragmentation 
of the m/z 880 Y-type ion. 
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Fragmentation of the m/z 880 (Y-type ion) indicated 3 possible structures. The 
m/z 676 originates from the loss of an internal hexose, while the m/z 662 
represents the loss of a terminal hexose. The m/z 458 and m/z 472 were difficult 
to distinguish due to several peaks in that area of the spectra. Subsequent 
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Figure 24. MS5 of m/z 1391.5, Man4GlcNAc2 LLO from C. elegans. Fragmentation of the m/z 
662 revealed several unexpected ions. 
Fragmentation of the m/z 662.2 (Y-type ion) produced an m/z AAA 
fragment only explainable by a tri-branching core. The m/z472 peak is also 
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present suggesting a mixture of linear and tri-branched core structures. Since 
fragmentation of the m/z 662 was preceded by the loss of two terminal hexoses, 
the branching point must be present on the second mannose of either the crt ,6 or 
c<1 ,3 arm. This was supported by the m/z 213 peak, a hexose with 2 hydroxyls. 
In addition the m/z 667 peak at the MS3 level also points to a non-core branching 
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Figure 25. Comparison of the MS spectra of m/z 1391.5, Man4GlcNAc2 LLO from C. elegans 
(panel A) and mouse macrophage(panel B). 
The tri-branching core structure has been found on proteins in C. elegans, 
but unexpected in the LLO pathway. There was no evidence of this isomer in 
the mouse macrophage cells and only the core branching structure was 
50 
identified. However, MS2 analysis again indicated the presence of a terminal 
HexNAc in the mouse macrophage cells. 
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Figure 26. MS4 of the m/z 1391.5, Man3GlcNAc2 LLO from mouse macrophage cells. 
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Figure 27. MS5 of the m/z 1391.5, Man4GlcNAc2 LLO from mouse macrophage cell and ion 
fragmentation assignment of the m/z 662 Y-type ion. 
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1391.5 -> 1098.4 (loss of - • ) -> 880.3 (loss of O ) - • 662.2 (loss of 1,2 
1391.5 -> 1098.4 (loss of - • ) -*• 880.3 (loss of O ) -> 662.2 (loss of 
Q-)458.1(lossof ~°~) 
1391.5 -+ 1098.4 (loss of - • ) -> 880.3 (loss of O ) - * 662.2 (loss of 
O)_>444.1(lossof Q-) 
1187.6 -> 894.4 (loss of - • ) -> 667.2 -» 563.2 
1187.6 -> 894.4 (loss of - • ) -> 676.2 -» 472.2 
1391.5—• 1098.4 (loss of " • ) 
O ) - ^ 213.0 
880.3 (loss of O ) - • 662.2 (loss of 
1187.6^928.4 (loss of • - ) 
1 
O 
Table 7. Table of the MSn pathways analyzed for Man4GlcNAc2 and the corresponding 
topologies. Structure 2 is unique to C. elegans. 
5.3.4 Comparative Structural Analysis MansGlcNAc? LLO 
The fragmentation pathway m/z 1595.8 -»• m/z 1302.6 -> m/z 1084.4 -> 
m/z 866.4 revealed the loss of two terminal hexoses and suggested a branching 
structure in the C. elegans sample. The loss of a third terminal hexose was 
observed at the MS5 level by the fragementation of the m/z 866 -» m/z 662. This 
indicated the presence of a branching structure similar to the standard 
Man5GlcNAc2 glycan found on proteins. 
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The expected LLO structure contains only one branching point at the first 
mannose and should only allow for the loss of two terminal hexoses. The crt ,6 
branch should not be completed until Man7GlcNAc2 in LLO samples. The 
fragmentation pathway m/z 1595.8 -» m/z 1302.6 -»• m/z 1084.4 -»• m/z 880 
suggested the presence of the expected Man5GlcNAc2 structure. However, the 
ion products m/z 505, m/z 519 and m/z 533 from the fragmentation of the m/z 
880 suggest an extension on the a1,6 arm. 
Careful review of the data suggested several additional unexpected 
structures. The m/z472 peak was observed at the MS6 level by the 
fragmentation pathway m/z 1595.8-» m/z 1302.6 -*• m/z 1084.4 -> m/z 866 - • 
m/z 648. The production of both the m/z 472 and m/z 458 ions proposes a 
mixture of branched and linear cores, a reiterated pattern seen in C. elegans 
LLO. However, a completely linear structure was unable to fully explain several 
fragmentation pathways since the m/z 880 and m/z866.4 fragments suggest a 
branching structure. In addition, it was possible for the m/z 1302.6 to lose 3 
terminal hexoses. Therefore, a tri-branching type structure was also proposed 
and is supported by several fragmentation pathways. If the tri-branch occurs at 
the second hexose, the m/z 472 can still be produced from the fragmentation of 
the m/z 648. Furthermore, this structure is supported by the m/z 871 ion 
produced from the fragmentation of the m/z 1302 peak at the MS2 level. 
Unfortunately, this structure was not completely confirmed through analysis of 
the m/z 871 due to limited sample amount. Interestingly, the m/z AAA ion is 
54 
again present at MS6 of the m/z 648 which suggested the possibility of the tri-
branching core previously identified in the Man4GlcNAc2 composition. 
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Figure 28. MS of the m/z 1595.8, Man5GlcNAc2 LLO from C. elegans and ion fragmentation 
assignment of the m/z 866 Y-type ion. This fragmentation pathway suggests a structure similar to 
the Man5GlcNAc2 commonly found on proteins. 
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Figure 29. MS4 of the m/z 1595.8, Man5GlcNAc2 LLO from C. elegansand ion fragmentation 
assignment of the m/z 880Y-type ion. Fragmentation of the m/z 880 ion suggests the presence of 
two core isomers. The m/z 676, m/z 505 and m/z 472 are indicative of a linear structure. The 
m/z 505, m/z 519 and, m/z533 suggest this extension is attached to the a1,6 arm. 
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Figure 30. MS of the m/z 1595.8, Man3GlcNAc2 LLO from C. elegans and ion fragmentation 
assignment of the m/z 667. 
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Figure 31. MS of the m/z 1595.8, Man3GlcNAc2 LLO from C. elegans and ion fragmentation 
assignment of the m/z 648 Y-ion. 
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Figure 32. MS of m/z 1595.8, Man5GlcNAc2 LLO from mouse macrophage cells. 
MSn disassembly of m/z 1595.8, Man5GlcNAc2, isolated from the mouse 
macrophage cell line indicates 3 structures are present. The fragmentation 
pathway, m/z 1595.8^ m/z 1302.6 -> m/z 1084.4 -»• m/z -> m/z 866.4 is 
consistent with the branching structure found in C. elegans. Again, this structure 
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is normally found on proteins after Golgi processing. The fragmentation of the 
m/z 667 supports this branching structure. The fragmentation pathway m/z 
1595.8-> m/z 1302.6 -»• m/z 1084.4 -*• m/z 880 indicates core branching pattern 
found in the expected LLO structures. The linear and tri-branching core was not 
observed in the mouse macrophage sample in the Man5GlcNAc2 composition. 
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Figure 33. MS5of m/z 1595.8, Man5GlcNAc2 from mouse macrophage cells and ion fragmentation 
of the m/z 667 C-type ion. 
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Figure 34. MS of m/z 1595.8, Man5GlcNAc2 from mouse macrophage cells and ion 
fragmentation of the m/z 880 Y-type ion and m/z 445 B-type ion. 
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MS" Pathways Man5GlcNAc2 LLO Consistent 
Topologies 
1595.8 -+ 1377.7 (loss of O) -> 1084.4 (loss of • • ) 
O ) -> 648.2 (loss of O ) -> 458.1 (*>•- ) 
866.4 (loss of 1 
1595.8 -> 1377.7 (loss of O ) -> 1159.6 (loss of O ) 
O ) -> 648.2 (loss of - • ) 
941.6 (loss of 
1595.8 -> 1377.7 (loss of O ) -+ 1084.4 (loss of " • ) 
QOO.c, -type ion) -+375.1 
667.4 ( 
1595.8 -+1302.6 (loss of 
O O O . C3-type ion) -
• ) -+1084.4 (loss of O ) 
563.4 
667.4 ( 
1595.8 -+ 1302.6 (loss of " • ) -+ 1084.4 (loss of O ) 
O O O , C3-type ion) -+ 227 ( O ) 
667.4 ( 
1595.8 -> 1377.7 (loss of O ) 
O ) -^662.1 (loss of - O ) 
1084.4 (loss of " • ) -+ 866.4 (loss of 
1595.8 -> 1377.7 (loss of O ) -» 1084.4 (loss of " • ) 
Q- ) -> 621.3 (loss of-••)-»• 417.0 
866.4 (loss of 
1595.8 -+ 1377.7 (loss of O ) -+ 1084.4 (loss of 
&-)-+ 621.3 (loss of • • ) -> 227.0 ( O ) 
I) -»• 866.4 (loss of 
1595.8 -> 880.4 -» 667.4 ( O O O ) 
1595.8 -> 445.3 (Q-Q, B2-type ion) -»301 2,3 
1595.8 -»• 445.3 ( O O , B2-type ion) -> 343.1 2,3 
1595.8 1302.6 (loss of Hi) -H. 1084.4 (loss of O ) -> 880.4 (loss of 2,3 
1595.8 - • 1302.6 (loss of - • ) -> 1084.4 (loss of O ) 
- O ) -» 635.3 (loss of - * ) -» 533.1 
880.4 (loss of 
1595.8 -> 1302.6 (loss of - • ) -> 1084.4 (loss of O ) 
635.3 (loss of -•-)—> 547.3 
880.4 (loss of 
1595.8-+1302.6 (loss of 
- O ) -> 662.4 (loss of P ) 
I) -»• 1084.4 (loss of O-) -> 880.4 (loss of 
1595.8^547.3 4 35A2 ion) 241.0 ( P ) 2,3 1595.8 -»• 547.3 (3'5A2 ion) -> 329.1 (loss of O ) 2,3 
9 9 
Table 8. Table of the MSn pathways analyzed and the corresponding topologies 
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MSn Pathways Man5GlcNAc2 LLO 
1595.8 -> 1302.6 (loss of " • ) -> 1084.4 (loss of O ) - * 866.4 (loss of 
O ) -^648.4 (loss of O ) -> 444.3 
1595.8 -> 1302.6 (loss of " • ) - • 1084.4 (loss of O ) - * 866.4 (loss of 
O ) -*648.4 (loss of O ) - * 472.3 










Table 9. Table of the MSn pathways analyzed and the corresponding topologies 
5.4 Future Directions 
The next direction of this project would be to continue with LLO 
comparative structural analysis targeting specific molecular compositions with 
biological significance in mind. The most interesting target would be the mature 
precursor GIC3Man9GlcNAc2- However, the lack of LLO material prevents 
extensive MSn analysis required for such a large structure. Very large scale 
extractions would be required to properly isolate enough material to investigate 
the larger LLOs. 
Isolation of dolichol linked glycans by liquid-liquid extractions is probably 
not exclusive to LLOs. Free glycans, glycosphingolipids and other lipid linked 
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glycan are most likely extracted as well. Dialysis of the extracts should remove 
any lower molecular weight molecules, eliminating the majority of free glycans 
normally found in the cytosol. However, MSn analysis of the intact precursor 
would be the next suitable course of action to confirm results reported here. 
MS2 of the entire LLO precursor has been completed by other laboratories. 
Larger molecular weights and various dolichol repeating units confound the 
identification through MS. Dol(19)-pp- GlcNAc2Man9Glc3 has been identified as 
the major constituent (Garrett, Guan et al. 2007). Intact LLO MSn analysis was 
attempted without any success. 
Another issue to address would be the relationship between the LLOs and 
glycans found on glycoproteins. As stated earlier, the exoglycosidases of the 
ER and Golgi are capable of extensively trimming down the transferred glycan 
precursor and this is believed to always occur with the exception of non secreted 
ER resident glycoprotiens. Therefore, there are two experiments to address this 
issue. Exoglycosysidase inhibitors such as castanospermine could be used to 
prevent trimming of transferred glycans in vivo. Following a certain incubation 
time with these inhibitors the N-glycans could be released from the glycoproteins 
protein and analyzed via MSn. This should be able to identify the primary 
isomers that are at least transferred to the glycoprotein. Secondly, ER resident 
proteins containing high mannose type glycans could also be targeted for study. 
This would have to involve a targeting and purification of specific glycoproteins 
most likely with the use of affinity chromatography prior to MSn analysis. 
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Once the isomers of the LLO pathway are extensity catalogued 
comparisons could be made to diseased states. For example, wild type mouse 
macrophage cells could be compared to cancerous cells. As many of the 
glycosylation pathways appeared altered in cancerous states it is likely the LLO 
pathway is aberrant under changes in cellular metabolism. 
5.5 Conclusions 
Identifying structural isomers in the LLO pathway highlights the unknown 
degree of variability associated with /V-glycosylation. Although, this data cannot 
directly prove any biological significance, it questions decade old theory believed 
to be factual. LLO structural isomers may not have a large impact on the overall 
biology of the cell, especially if they are simply discarded. 
This project identified several structural isomers in the series 
Man3GlcNAc2 through Man5GlcNAc2. The overall pattern in C. elegans suggests 
increasing structural diversity with an increase in carbohydrate residues. This 
also applies to mouse macrophage cell albeit to a lesser extent. The unique tri-
branching structure identified in C. elegans could not be found in the mouse 
macrophage cells. However, mouse macrophage cells contain an unexpected 
terminal HexNAc structure. Interestingly, the linear glycan appears in both C. 
elegans and mouse macrophage samples. However, in the mouse macrophage, 


























































































































































































The widely accepted LLO standard tri-mannosyl core was identified in 
both samples. This could be the primary structure that is synthesized by the 
LLO pathway. However, the number of other isomers identified questions the 
overall specificity of the enzymes of this pathway. In addition, these isomers 
would not be detected by HPLC or other glycoanalytic techniques that do not 
employ MSn. Therefore, they must be considered when interpreting data from 
these methods. Even if they are identified as free glycans or products of 
degradation they will contribute to results obtained by non MSn methods since 
the extraction protocol followed here was adapted from other methods. 
In summary the MSn techniques employed here provided a detailed 
structural analysis of the isolated carbohydrates. The results indicate a range of 
different structural isomers for each molecular composition. Although the source 
of these isomers is questionable, their presence is obvious. Hopefully continual 
investigation of the LLO pathway with techniques described here will aid in the 
elucidation and understanding of A/-glycosylation. 
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